{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:51:30Z","timestamp":1785891090458,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/bf03262000","type":"journal-article","created":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T20:21:15Z","timestamp":1357244475000},"page":"1147-1158","source":"Crossref","is-referenced-by-count":9,"title":["Reasons for and Time to Discontinuation of Rimonabant Therapy"],"prefix":"10.1007","volume":"35","author":[{"given":"Marjolein J. C.","family":"Willemen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aukje K.","family":"Mantel-Teeuwisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Buggy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Layton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine M. J. M.","family":"Straus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert G. M.","family":"Leufkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toine C. G.","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,13]]},"reference":[{"key":"2000_CR1","unstructured":"Summary of product characteristics: Acomplia. Paris: Sanofi-Aventis, 2006 [online]. Available from URL: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000666\/WC500021287.pdf [Accessed 2010 Dec 20]"},{"issue":"2","key":"2000_CR2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.neuropharm.2006.03.029","volume":"51","author":"F.J. Pavon","year":"2006","unstructured":"Pavon FJ, Bilbao A, Hernandez-Folgado L, et al. Anti-obesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole-LH 21. Neuropharmacology 2006; 51(2): 358\u201366","journal-title":"Neuropharmacology"},{"issue":"1","key":"2000_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.expneurol.2010.03.018","volume":"224","author":"D. Parolaro","year":"2010","unstructured":"Parolaro D, Realini N, Vigano D, et al. The endocannabinoid system and psychiatric disorders. Exp Neurol 2010; 224(1): 3\u201314","journal-title":"Exp Neurol"},{"key":"2000_CR4","unstructured":"European Public Assessment Report (EPAR) for Acomplia\u00ae. Committee for Medicinal Products for Human Use (CHMP) [online]. Available from URL: http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/acomplia\/acomplia.htm [Accessed 2010 Aug 03]"},{"issue":"13","key":"2000_CR5","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1001\/jama.299.13.1601","volume":"299","author":"J.S. Rumsfeld","year":"2008","unstructured":"Rumsfeld JS, Nallamothu BK. The hope and fear of rimonabant. JAMA 2008; 299(13): 1601\u20132","journal-title":"JAMA"},{"key":"2000_CR6","unstructured":"The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. Committee for Medicinal Products for Human Use [online]. Available from URL: http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/acomplia\/53777708en.pdf [Accessed 2010 Aug 24]"},{"issue":"6","key":"2000_CR7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2165\/11588510-000000000-00000","volume":"34","author":"Y. Buggy","year":"2011","unstructured":"Buggy Y, Cornelius V, Wilton L, et al. Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England. Drug Saf 2011; 34(6): 501\u20139","journal-title":"Drug Saf"},{"issue":"2","key":"2000_CR8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","volume":"126","author":"D.L. Hershman","year":"2011","unstructured":"Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011; 126(2): 529\u201337","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"2000_CR9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jama.299.5.532","volume":"299","author":"P.M. Ho","year":"2008","unstructured":"Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299(5): 532\u20139","journal-title":"JAMA"},{"issue":"3","key":"2000_CR10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00223-009-9329-4","volume":"86","author":"M. Hiligsmann","year":"2010","unstructured":"Hiligsmann M, Rabenda V, Gathon HJ, et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 2010; 86(3): 202\u201310","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2000_CR11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-2005-864122","volume":"38","author":"G.W. Hugenholtz","year":"2005","unstructured":"Hugenholtz GW, Heerdink ER, Meijer WE, et al. Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 2005; 38(3): 122\u20134","journal-title":"Pharmacopsychiatry"},{"issue":"12","key":"2000_CR12","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00228-007-0375-4","volume":"63","author":"E.C. Geffen Van","year":"2007","unstructured":"Van Geffen EC, van der Wal SW, van Hulten R, et al. Evaluation of patients\u2019 experiences with antidepressants reported by means of a medicine reporting system. Eur J Clin Pharmacol 2007; 63(12): 1193\u20139","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"2000_CR13","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.rmed.2004.01.014","volume":"98","author":"N.S. Breekveldt-Postma","year":"2004","unstructured":"Breekveldt-Postma NS, Gerrits CM, Lammers JW, et al. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med 2004; 98(8): 752\u20139","journal-title":"Respir Med"},{"issue":"9","key":"2000_CR14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/hrt.2003.026187","volume":"90","author":"A.K. Mantel-Teeuwisse","year":"2004","unstructured":"Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, et al. Long term persistence with statin treatment in daily medical practice. Heart 2004; 90(9): 1065\u20136","journal-title":"Heart"},{"issue":"11","key":"2000_CR15","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/01.hjh.0000187261.40190.2e","volume":"23","author":"B.L. Wijk Van","year":"2005","unstructured":"Van Wijk BL, Klungel OH, Heerdink ER, et al. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23(11): 2101\u20137","journal-title":"J Hypertens"},{"issue":"2","key":"2000_CR16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1345\/aph.1K516","volume":"42","author":"E.C. Geffen Van","year":"2008","unstructured":"Van Geffen EC, van Hulten R, Bouvy ML, et al. Characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor treatment. Ann Pharmacother 2008; 42(2): 218\u201325","journal-title":"Ann Pharmacother"},{"key":"2000_CR17","unstructured":"BBC News. Weight loss pill warning issued, 19 July 2007 [online]. Available from URL: http:\/\/news.bbc.co.uk\/2\/hi\/health\/6907160.stm [Accessed 2012 Jan 10]"},{"key":"2000_CR18","unstructured":"The Telegraph. Study links slimming drug to depression, 15 November 2007 [online]. Available from URL: http:\/\/www.telegraph.co.uk\/news\/uknews\/1569548\/Study-links-slimming-drug-to-depression.html [Accessed 2012 Jan 10]"},{"key":"2000_CR19","unstructured":"Daily Mail. Weight-loss pill taken by 40,000 \u2018can lead to suicidal thought\u2019, 15 November 2007 [online]. Available from URL: http:\/\/www.dailymail.co.uk\/health\/article-494365\/Weight-loss-pill-taken-40-000-lead-suicidal-thoughts.html [Accessed 2012 Jan 10]"},{"issue":"7","key":"2000_CR20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/pds.1759","volume":"18","author":"M.J. Willemen","year":"2009","unstructured":"Willemen MJ, Mantel-Teeuwisse AK, Straus SM, et al. Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti-obesity drugs. Pharmacoepidemiol Drug Saf 2009; 18(7): 631\u20138","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"2000_CR21","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1038\/oby.2008.362","volume":"16","author":"M.J. Willemen","year":"2008","unstructured":"Willemen MJ, Mantel-Teeuwisse AK, Straus SM, et al. Psychiatric and cardiovascular co-morbidities in patients with diabetes mellitus starting anti-obesity drug. Obesity (Silver Spring) 2008; 16(10): 2331\u20135","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"2000_CR22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11593830-000000000-00000","volume":"34","author":"D. Layton","year":"2011","unstructured":"Layton D, Hazell L, Shakir S. Modified prescription-event monitoring studies. Drug Saf 2011; 34(12): e1\u20139","journal-title":"Drug Saf"},{"issue":"12","key":"2000_CR23","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.2337\/dc08-1341","volume":"31","author":"J.S. Gonzalez","year":"2008","unstructured":"Gonzalez JS, Peyrot M, McCarl LA, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 2008; 31(12): 2398\u2013403","journal-title":"Diabetes Care"},{"issue":"2","key":"2000_CR24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.schbul.a007076","volume":"30","author":"M. Valenstein","year":"2004","unstructured":"Valenstein M, Blow FC, Copeland LA, et al. Poor anti-psychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30(2): 255\u201364","journal-title":"Schizophr Bull"},{"issue":"10","key":"2000_CR25","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1176\/appi.ajp.159.10.1653","volume":"159","author":"A. Zygmunt","year":"2002","unstructured":"Zygmunt A, Olfson M, Boyer CA, et al. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002; 159(10): 1653\u201364","journal-title":"Am J Psychiatry"},{"key":"2000_CR26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1192\/bjp.183.3.197","volume":"183","author":"M. Nose","year":"2003","unstructured":"Nose M, Barbui C, Gray R, et al. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry 2003; 183: 197\u2013206","journal-title":"Br J Psychiatry"},{"key":"2000_CR27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L. Hazell","year":"2006","unstructured":"Hazell L, Shaki SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 385\u20136","journal-title":"Drug Saf"},{"key":"2000_CR28","unstructured":"Acomplia: procedural steps taken and scientific information after authorisation [online]. Available from URL: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation\/human\/000666\/WC500021286.pdf [Accessed 2010 Dec 12]"},{"issue":"21","key":"2000_CR29","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2008.12.068","volume":"53","author":"C.J. Lavie","year":"2009","unstructured":"Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53(21): 1925\u201332","journal-title":"J Am Coll Cardiol"},{"issue":"7121","key":"2000_CR30","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/nature05482","volume":"444","author":"S.E. Kahn","year":"2006","unstructured":"Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444(7121): 840\u20136","journal-title":"Nature"},{"issue":"6","key":"2000_CR31","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1053\/j.gastro.2007.03.050","volume":"132","author":"E. Giovannucci","year":"2007","unstructured":"Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007; 132(6): 2208\u201325","journal-title":"Gastroenterology"},{"issue":"2","key":"2000_CR32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1345\/aph.1E027","volume":"39","author":"B.L. Wijk Van","year":"2005","unstructured":"Van Wijk BL, Klungel OH, Heerdink ER, et al. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Ann Pharmacother 2005; 39(2): 319\u201328","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2000_CR33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MLR.0b013e3181808c17","volume":"47","author":"P.J. Nietert","year":"2009","unstructured":"Nietert PJ, Tilley BC, Zhao W, et al. Two pharmacy interventions to improve refill persistence for chronic disease medications: a randomized, controlled trial. Med Care 2009; 47(1): 32\u201340","journal-title":"Med Care"},{"issue":"10","key":"2000_CR34","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1345\/aph.1K151","volume":"41","author":"M. Machado","year":"2007","unstructured":"Machado M, Bajcar J, Guzzo GC, et al. Sensitivity of patient outcomes to pharmacist interventions, part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother 2007; 41(10): 1569\u201382","journal-title":"Ann Pharmacother"},{"issue":"11","key":"2000_CR35","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1345\/aph.1K311","volume":"41","author":"M. Machado","year":"2007","unstructured":"Machado M, Bajcar J, Guzzo GC, et al. Sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. Ann Pharmacother 2007; 41(11): 1770\u201381","journal-title":"Ann Pharmacother"},{"key":"2000_CR36","first-page":"307","volume-title":"Prescription-event monitoring. In: Mann RD, Andrews EB, editors. Pharmacovigilance","author":"S. Shakir","year":"2007","unstructured":"Shakir S. Prescription-event monitoring. In: Mann RD, Andrews EB, editors. Pharmacovigilance. Chichester: John Wiley & Sons Ltd, 2007: 307\u201316"},{"issue":"7059","key":"2000_CR37","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/bmj.313.7059.732","volume":"313","author":"B.R. McAvoy","year":"1996","unstructured":"McAvoy BR, Kaner EF. General practice postal surveys: a questionnaire too far? BMJ 1996; 313(7059): 732\u20133","journal-title":"BMJ"},{"issue":"7151","key":"2000_CR38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/bmj.317.7151.119","volume":"317","author":"R.M. Martin","year":"1998","unstructured":"Martin RM, Kapoor KV, Wilton LV, et al. Underreporting of suspected adverse drug reactions to newly marketed (\u2018black triangle\u2019) drugs in general practice: observational study. BMJ 1998; 317(7151): 119\u201320","journal-title":"BMJ"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03262000.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03262000\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03262000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T01:41:49Z","timestamp":1558489309000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03262000"}},"subtitle":["A Modified Prescription-Event Monitoring Study"],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["2000"],"URL":"https:\/\/doi.org\/10.1007\/bf03262000","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}